Kintor Pharmaceutical Limited
Kintor Pharmaceutical Limited, a clinical-stage novel drug developer, focuses on developing small molecules and biologic drugs for dermatology and oncology in the People's Republic of China. Its product candidates include KX-826, a potential topical drug for the treatment of androgenic alopecia (AGA) and acne vulgaris, which is in phase III clinical trial; and GT20029, a topical AR-PROTAC compoun… Read more
Kintor Pharmaceutical Limited (KNTPF) - Total Liabilities
Latest total liabilities as of June 2025: $175.89 Million USD
Based on the latest financial reports, Kintor Pharmaceutical Limited (KNTPF) has total liabilities worth $175.89 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kintor Pharmaceutical Limited - Total Liabilities Trend (2014–2024)
This chart illustrates how Kintor Pharmaceutical Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Kintor Pharmaceutical Limited Competitors by Total Liabilities
The table below lists competitors of Kintor Pharmaceutical Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
COWINTECH Co. Ltd
KQ:282880
|
Korea | ₩159.03 Billion |
|
Shelf Drilling Ltd
PINK:SHLLF
|
USA | $1.56 Billion |
|
President Bakery Public Company Limited
BK:PB
|
Thailand | ฿1.13 Billion |
|
Crimson Wine
OTCQB:CWGL
|
USA | $32.01 Million |
|
Arbor Technology
TWO:3594
|
Taiwan | NT$2.34 Billion |
|
Genovate Biotechnology Co Ltd
TWO:4130
|
Taiwan | NT$126.05 Million |
|
Aminex PLC
PINK:AEXFF
|
USA | $15.15 Million |
|
IOL Chemicals and Pharmaceuticals Limited
NSE:IOLCP
|
India | ₹6.62 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Kintor Pharmaceutical Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kintor Pharmaceutical Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kintor Pharmaceutical Limited (2014–2024)
The table below shows the annual total liabilities of Kintor Pharmaceutical Limited from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $221.05 Million | -46.23% |
| 2023-12-31 | $411.12 Million | -26.58% |
| 2022-12-31 | $559.95 Million | +35.64% |
| 2021-12-31 | $412.83 Million | +20.17% |
| 2020-12-31 | $343.54 Million | +186899.76% |
| 2019-12-31 | $183.71K | +6.86% |
| 2018-12-31 | $171.92K | -99.62% |
| 2017-12-31 | $45.51 Million | +45226.62% |
| 2016-12-31 | $100.39K | -74.18% |
| 2015-12-31 | $388.81K | -2.07% |
| 2014-12-31 | $397.01K | -- |